TN2009000331A1 - Derives de 3-amino-pyrrolo [3,4-c]pyrazole -5- (1h,4h,6h) carbaldehyde servant d'inhibiteurs de pkc - Google Patents
Derives de 3-amino-pyrrolo [3,4-c]pyrazole -5- (1h,4h,6h) carbaldehyde servant d'inhibiteurs de pkcInfo
- Publication number
- TN2009000331A1 TN2009000331A1 TNP2009000331A TN2009000331A TN2009000331A1 TN 2009000331 A1 TN2009000331 A1 TN 2009000331A1 TN P2009000331 A TNP2009000331 A TN P2009000331A TN 2009000331 A TN2009000331 A TN 2009000331A TN 2009000331 A1 TN2009000331 A1 TN 2009000331A1
- Authority
- TN
- Tunisia
- Prior art keywords
- pyrrolo
- pyrazole
- amino
- disease
- pkc inhibitors
- Prior art date
Links
- GPWNWKWQOLEVEQ-UHFFFAOYSA-N 2,4-diaminopyrimidine-5-carbaldehyde Chemical class NC1=NC=C(C=O)C(N)=N1 GPWNWKWQOLEVEQ-UHFFFAOYSA-N 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000027866 inflammatory disease Diseases 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 208000028867 ischemia Diseases 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Oncology (AREA)
- Virology (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La présente invention concerne des composés et sels pharmaceutiquement acceptables de formules A et B : dans lesquelles A, B, R1, R2, R3, R4, R5, R6, R7, R8, R9 et R10 répondent aux définitions précitées. L'invention concerne en outre des compositions pharmaceutiques comprenant les composés et sels pharmaceutiquement acceptables et des méthodes de traitement du diabète sucré et de ses complications, du cancer, d'une ischémie, de l'inflammation, de troubles du système nerveux central, d'une maladie cardiovasculaire, de la maladie d'Alzheimer et d'une maladie dermatologique, de maladies virales, de troubles inflammatoires, ou de maladies dans lesquelles le foie est un organe cible.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US88874907P | 2007-02-07 | 2007-02-07 | |
| US98908607P | 2007-11-19 | 2007-11-19 | |
| US2096508P | 2008-01-14 | 2008-01-14 | |
| PCT/IB2008/000297 WO2008096260A1 (fr) | 2007-02-07 | 2008-02-04 | Nouveaux dérivés de 3-amino-pyrrolo[3,4-c]pyrazole-5(1h,4h,6h) carbaldéhyde |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TN2009000331A1 true TN2009000331A1 (fr) | 2010-12-31 |
Family
ID=39493354
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TNP2009000331A TN2009000331A1 (fr) | 2007-02-07 | 2009-08-05 | Derives de 3-amino-pyrrolo [3,4-c]pyrazole -5- (1h,4h,6h) carbaldehyde servant d'inhibiteurs de pkc |
Country Status (19)
| Country | Link |
|---|---|
| US (6) | US8183255B2 (fr) |
| EP (1) | EP2118112B1 (fr) |
| JP (1) | JP5161245B2 (fr) |
| KR (1) | KR101060892B1 (fr) |
| AP (1) | AP2009004958A0 (fr) |
| AU (1) | AU2008212625B2 (fr) |
| BR (1) | BRPI0807346B8 (fr) |
| CA (1) | CA2677572C (fr) |
| CR (1) | CR10968A (fr) |
| DO (1) | DOP2009000201A (fr) |
| EA (1) | EA017937B1 (fr) |
| EC (1) | ECSP099569A (fr) |
| IL (1) | IL200270A (fr) |
| MA (1) | MA31178B1 (fr) |
| MX (1) | MX2009008546A (fr) |
| NZ (1) | NZ578876A (fr) |
| TN (1) | TN2009000331A1 (fr) |
| WO (1) | WO2008096260A1 (fr) |
| ZA (1) | ZA200906032B (fr) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2677572C (fr) | 2007-02-07 | 2012-12-18 | Pfizer Inc. | Nouveaux derives de 3-amino-pyrrolo[3,4-c]pyrazole-5(1h,4h,6h) carbaldehyde |
| WO2011090738A2 (fr) | 2009-12-29 | 2011-07-28 | Dana-Farber Cancer Institute, Inc. | Inhibiteurs de kinase raf de type ii |
| WO2011107494A1 (fr) | 2010-03-03 | 2011-09-09 | Sanofi | Nouveaux dérivés aromatiques de glycoside, médicaments contenants ces composés, et leur utilisation |
| EP2582709B1 (fr) | 2010-06-18 | 2018-01-24 | Sanofi | Dérivés d'azolopyridin-3-one en tant qu'inhibiteurs de lipases et de phospholipases |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| US9382229B2 (en) | 2011-02-15 | 2016-07-05 | The Johns Hopkins University | Compounds and methods of use thereof for treating neurodegenerative disorders |
| CN102093366B (zh) * | 2011-03-04 | 2012-11-28 | 中国医学科学院医药生物技术研究所 | 双环氨基吡唑类化合物及其在抗柯萨奇病毒中的应用 |
| WO2013037390A1 (fr) | 2011-09-12 | 2013-03-21 | Sanofi | Dérivés amides d'acide 6-(4-hydroxyphényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase |
| EP2567959B1 (fr) | 2011-09-12 | 2014-04-16 | Sanofi | Dérivés d'amide d'acide 6-(4-hydroxy-phényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase |
| WO2013045413A1 (fr) | 2011-09-27 | 2013-04-04 | Sanofi | Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b] pyridine-4-carboxylique utilisés comme inhibiteurs de kinase |
| US9382239B2 (en) | 2011-11-17 | 2016-07-05 | Dana-Farber Cancer Institute, Inc. | Inhibitors of c-Jun-N-terminal kinase (JNK) |
| ES2658395T3 (es) | 2012-04-04 | 2018-03-09 | Rigel Pharmaceuticals, Inc. | Inhibidores de proteína cinasa C y usos de los mismos |
| KR102091895B1 (ko) * | 2012-05-03 | 2020-04-14 | 제넨테크, 인크. | 파킨슨병의 치료에 사용하기 위한 lrrk2 조절제로서의 피라졸 아미노피리미딘 유도체 |
| EP2909194A1 (fr) | 2012-10-18 | 2015-08-26 | Dana-Farber Cancer Institute, Inc. | Inhibiteurs de cycline-dépendante kinase 7 (cdk7) |
| USRE48175E1 (en) | 2012-10-19 | 2020-08-25 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged small molecules as inducers of protein degradation |
| WO2014063054A1 (fr) | 2012-10-19 | 2014-04-24 | Dana-Farber Cancer Institute, Inc. | Inhibiteurs de kinase moelle osseuse sur chromosome x (bmx) et leurs utilisations |
| US20140206667A1 (en) | 2012-11-14 | 2014-07-24 | Michela Gallagher | Methods and compositions for treating schizophrenia |
| CA2904610A1 (fr) | 2013-03-14 | 2014-09-25 | Rigel Pharmaceuticals, Inc. | Inhibiteurs de proteine kinase c et leurs utilisations |
| EP3057956B1 (fr) | 2013-10-18 | 2021-05-05 | Dana-Farber Cancer Institute, Inc. | Inhibiteurs polycycliques de la kinase cycline-dépendante 7 (cdk7) |
| WO2015058126A1 (fr) | 2013-10-18 | 2015-04-23 | Syros Pharmaceuticals, Inc. | Composés hétéroaromatiques utiles dans le traitement de maladies prolifératives |
| US9862688B2 (en) | 2014-04-23 | 2018-01-09 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged janus kinase inhibitors and uses thereof |
| WO2015164614A1 (fr) | 2014-04-23 | 2015-10-29 | Dana-Farber Cancer Institute, Inc. | Inhibiteurs de janus kinase et leurs utilisations |
| EP3145931B1 (fr) * | 2014-05-23 | 2021-03-31 | Mingsight Pharmaceuticals, Inc. | Traitement d'une maladie auto-immune |
| JP6854762B2 (ja) * | 2014-12-23 | 2021-04-07 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | サイクリン依存性キナーゼ７（ｃｄｋ７）の阻害剤 |
| USRE50776E1 (en) | 2015-03-27 | 2026-02-03 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
| WO2016201370A1 (fr) | 2015-06-12 | 2016-12-15 | Dana-Farber Cancer Institute, Inc. | Thérapie d'association utilisant des inhibiteurs de transcription et des inhibiteurs de kinases |
| AU2016319125B2 (en) | 2015-09-09 | 2021-04-08 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
| AU2016355303B2 (en) * | 2015-11-20 | 2021-10-07 | Mingsight Pharmaceuticals, Inc. | Treatment of autoimmune disease |
| CN106727582B (zh) * | 2015-11-20 | 2020-06-12 | 深圳明赛瑞霖药业有限公司 | 自身免疫疾病的治疗 |
| AU2017295858A1 (en) | 2016-07-14 | 2019-01-24 | Mingsight Pharmaceuticals, Inc. | Treatment of cancer |
| EP3630117A4 (fr) | 2017-05-25 | 2021-02-24 | Mingsight Pharmaceuticals, Inc. | Formes à l'état solide d'inhibiteur de pkc |
| RU2020114670A (ru) | 2017-10-11 | 2021-11-12 | Ф. Хоффманн-Ля Рош Аг | Бициклические соединения для применения в качестве ингибиторов rip1 киназы |
| US20210069194A1 (en) * | 2018-01-17 | 2021-03-11 | Mingsight Pharmaceuticals, Inc. | Combination therapy for the treatment of cancer |
| EP3810132A4 (fr) | 2018-06-25 | 2022-06-22 | Dana-Farber Cancer Institute, Inc. | Inhibiteurs de kinase de la famille taire et utilisations correspondantes |
| US12281126B2 (en) | 2018-12-28 | 2025-04-22 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 and uses thereof |
| WO2022261214A1 (fr) * | 2021-06-09 | 2022-12-15 | Mingsight Pharmaceuticals, Inc. | Compositions comprenant des inhibiteurs de pkc-bêta et procédés de préparation associés |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1320531T3 (da) | 2000-08-10 | 2011-01-03 | Pfizer Italia Srl | Bicyclo-pyrazoler, der er aktive som kinase inhibitorer, fremgangsmåde til fremstilling deraf og farmaceutiske sammensætninger, der indeholder disse |
| UA81790C2 (uk) * | 2002-12-19 | 2008-02-11 | Фармация Италия С.П.А. | Заміщені піролопіразольні похідні як інгібітори кінази |
| AU2005323797B2 (en) * | 2005-01-10 | 2009-07-09 | Pfizer Inc. | Pyrrolopyrazoles, potent kinase inhibitors |
| CA2677572C (fr) | 2007-02-07 | 2012-12-18 | Pfizer Inc. | Nouveaux derives de 3-amino-pyrrolo[3,4-c]pyrazole-5(1h,4h,6h) carbaldehyde |
-
2008
- 2008-02-04 CA CA2677572A patent/CA2677572C/fr active Active
- 2008-02-04 AP AP2009004958A patent/AP2009004958A0/xx unknown
- 2008-02-04 AU AU2008212625A patent/AU2008212625B2/en active Active
- 2008-02-04 EP EP08702370.1A patent/EP2118112B1/fr active Active
- 2008-02-04 BR BRPI0807346A patent/BRPI0807346B8/pt active IP Right Grant
- 2008-02-04 NZ NZ578876A patent/NZ578876A/xx unknown
- 2008-02-04 EA EA200970670A patent/EA017937B1/ru not_active IP Right Cessation
- 2008-02-04 US US12/523,965 patent/US8183255B2/en active Active
- 2008-02-04 MX MX2009008546A patent/MX2009008546A/es active IP Right Grant
- 2008-02-04 WO PCT/IB2008/000297 patent/WO2008096260A1/fr not_active Ceased
- 2008-02-04 KR KR1020097018673A patent/KR101060892B1/ko active Active
- 2008-02-04 JP JP2009548766A patent/JP5161245B2/ja active Active
-
2009
- 2009-08-05 TN TNP2009000331A patent/TN2009000331A1/fr unknown
- 2009-08-06 CR CR10968A patent/CR10968A/es unknown
- 2009-08-06 IL IL200270A patent/IL200270A/en not_active IP Right Cessation
- 2009-08-07 DO DO2009000201A patent/DOP2009000201A/es unknown
- 2009-08-07 MA MA32158A patent/MA31178B1/fr unknown
- 2009-08-07 EC EC2009009569A patent/ECSP099569A/es unknown
- 2009-08-31 ZA ZA2009/06032A patent/ZA200906032B/en unknown
-
2012
- 2012-04-18 US US13/450,388 patent/US8877761B2/en active Active
-
2014
- 2014-10-03 US US14/506,470 patent/US9518060B2/en active Active
-
2016
- 2016-12-12 US US15/376,279 patent/US10316045B2/en active Active
-
2019
- 2019-04-17 US US16/387,369 patent/US11220518B2/en active Active
-
2021
- 2021-12-01 US US17/539,948 patent/US11780853B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TN2009000331A1 (fr) | Derives de 3-amino-pyrrolo [3,4-c]pyrazole -5- (1h,4h,6h) carbaldehyde servant d'inhibiteurs de pkc | |
| Aboul-Fadl et al. | Schiff bases of indoline-2, 3-dione (isatin) derivatives and nalidixic acid carbohydrazide, synthesis, antitubercular activity and pharmacophoric model building | |
| MX2009010951A (es) | Derivados de 3-amino-pirrolo[3,4-c]pirazol-5(1h,4h,6h)-carbaldehid o como inhibidores de proteina quinasa c. | |
| US6624202B2 (en) | Inhibitors of copper-containing amine oxidases | |
| DE60103974T2 (de) | Gyrase-inhibitoren und ihre verwendung | |
| TWI577681B (zh) | 咪唑并嗒化合物 | |
| DE602004028150D1 (de) | Aminopyrazolderivate als gsk-3-inhibitoren | |
| ATE537175T1 (de) | Neue piperazino-dihydrothienopyrimidin-derivate | |
| MA30420B1 (fr) | Derives de terphenyle pour le traitment de la maladie d'alzheimer | |
| CA2662848C (fr) | Derives de 2-aryl-6-phenyl-imidazo[1,2-.alpha.]pyridines, leur preparation et leur application en therapeutique | |
| EA200870373A1 (ru) | Пиридил- и пиримидинилзамещённые производные пиррола, тиофена и фурана в качестве ингибиторов киназ | |
| TN2013000393A1 (fr) | Derives de la pyrazolospirocetone pour une utilisation comme inhibiteurs de l'acetyl-coa carboxylase | |
| MA38138A1 (fr) | Dérivés inédits de quinolone | |
| MA30821B1 (fr) | Derives de pyrazoline utiles comme antagonistes des recepteurs de mineralocorticoïdes | |
| TN2011000252A1 (fr) | Lactames servant d'inhibiteurs de beta-secretase | |
| TN2009000483A1 (fr) | Derives de 7-alkynyl-1-8-naphthyridones, leur preparation et leur application en therapeutique | |
| UA96618C2 (en) | 3-amino-pyrrolo[3,4-c] pyrazole- 5 (1h, 4h, 6h) carbaldehyde derivatives as pkc inhibitors | |
| EP2150550A4 (fr) | Nouveau composé carbamoyloxy aryle alcane arylpipérazine, compositions pharmaceutiques comprenant ce composé et méthode de traitement de la douleur, de l'anxiété et de la dépression par administration de ce composé | |
| JP2021515019A (ja) | ピロリジンアミド誘導体及びその使用 | |
| MA27716A1 (fr) | 4-aminopyrimidine-5-one | |
| TNSN08138A1 (fr) | Derives d'imidazole pour le traitement de troubles neurologiques | |
| ATE444069T1 (de) | Chinolin-derivate zur behandlung von mglur5- rezeptor-vermittelten erkrankungen | |
| CN106986859A (zh) | 吲哚衍生物及其用途 | |
| WO2005080319A1 (fr) | Derives d'hydrazino alcool utiles en tant qu'inhibiteurs d'amine-oxydases contenant du cuivre | |
| JP2001523659A (ja) | 細胞外グルタミン酸濃度を低下させるための４位置換２−ピロリジノン誘導体 |